Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal PD-1 Antibody in Leptomeningeal Disease
2024-514068-14-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Carcinomatous Meningitis (CM) and solid tumor, sponsored by University Hospital Tübingen. Primary endpoints: Maximum tolerable dose of intrathecal PD-1 antibody and Safety of intrathecal PD-1 antibody administration. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
Carcinomatous Meningitis (CM)solid tumor
Beyond the preview
Go deeper on 2024-514068-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514068-14-00.